- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03808168
Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia
17 de enero de 2019 actualizado por: University of Texas Southwestern Medical Center
Phase II Trial of Nivolumab Based Immunotherapy for the Treatment of High-Grade Cervical Dysplasia
The study design is a phase II interventional trial for women with biopsy proven high-grade cervical dysplasia.
The study is an open label study and randomized.
The study will have two arms.
Patients will be randomized to both arms.
Descripción general del estudio
Descripción detallada
High-grade cervical dysplasia (cervical intraepithelial neoplasia (CIN) II/III), is both detectable and quantifiable, which presents many opportunities for evaluation or early treatment, intervention and eventually, for cancer prevention.
High-grade dysplasia is typically detected during cervical cancer screening with a pap smear.
To determine the pathologic response rate of high grade cervical dysplasia with PD-1 checkpoint modulation with Nivolumab.This is a randomized phase II trial with two experimental arms (1 dose of nivolumab and 3 doses of nivolumab).
Tipo de estudio
Intervencionista
Fase
- Fase 2
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Femenino
Descripción
Inclusion Criteria:
- Adult female subjects (age 18 years or older)
- Performance status ECOG 0-1
- All patients must have cervical biopsies demonstrating high-grade cervical dysplasia.
- All patients must have a satisfactory colposcopy with visualization of the entire squamo-columnar junction
- All patients must be candidates for a cervical conization procedure or LEEP procedure
- The patient is able and willing to comply with study procedures, and signed and dated informed consent is obtained before any study-related procedure is performed
- Negative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virus
- At least six weeks must have elapsed from any prior chemotherapy, radiation therapy or immunotherapy
Patients must have adequate:
- Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl. Platelets greater than or equal to100, 000/mcl. Hemoglobin > 9 gm/dL.
- Renal function: creatinine less than or equal to institutional upper limit normal (ULN) or calculated creatinine clearance (Cockcroft-Gault) ≥ 50 ml/min.
- Serum creatinine </= 1.5xULN or creatinine clearance (CrCl) >/=50 mL/min (using the Cockcroft-Gault formula)
- Female CrCl = (140-age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL
- Metabolic function: Calcium, Magnesium, Phosphate, and Potassium levels within institutional normal limits.
- Hepatic function: Bilirubin less than or equal to 1.5 x ULN. AST and ALT less than or equal to 3 ULN and alkaline phosphatase less than or equal to 2.5 x ULN.
- Patients must have signed an approved informed consent and authorization permitting release of personal health information.
- Patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception. The effects of Nivolumab on the developing human fetus are unknown. For this reason and because other therapeutic agents or modalities used in this trial are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, through the duration of study participation and for a period of 5 months after the last dose of nivolumab. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Exclusion Criteria:
- The patient is lactating or pregnant
- The colposcopy is inadequate; the entire transformation zone is not visualized and endocervical curettage is positive for high-grade dysplasia
- Clinical concern for invasive cervical cancer
- Patients must not have received any prior oncology vaccine therapy
- Intercurrent medical illnesses that would impair patient tolerance to participation
- Any concurrent medical condition requiring the use of systemic steroids is not permitted (the use of inhaled or topic steroids is permitted)
- Concurrent treatment with chemotherapy, radiation therapy or immunotherapy for intercurrent illnesses
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results;
- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways;
- Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll;
- Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- Subjects with history of life-threatening toxicity, including hypersensitivity reaction, related to prior immunoglobulin treatment for another condition or any other study drug component.
- History or evidence upon physical/neurological examination of other central nervous system condition (e.g., seizures, abscess) unrelated to cancer, unless adequately controlled by medication or considered not potentially interfering with protocol treatment;
- Surgical procedure <7 days prior to study treatment, vascular access device no restriction;
- Subjects unable (e.g., due to pacemaker or ICD device) or unwilling to have a contrast-enhanced MRI of the head;
- History of allergy or hypersensitivity to study drug components
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Arm 1
Nivolumab, 3 mg/kg Iv, day 1
|
Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
Otros nombres:
|
Comparador activo: Arm 2
Nivolumab, 3 mg/kg IV, days 1, 15, 29
|
Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Rate of regression on high grade dysplasia lesions
Periodo de tiempo: 15 weeks after the beginning of immunotherapy
|
The endpoints of the current study will be to determine the rate of spontaneous regression on high grade dysplasia lesions
|
15 weeks after the beginning of immunotherapy
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Jayanthi Lea, MD, Univeristy of Texas Southwestern Medical Center
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Anticipado)
15 de enero de 2019
Finalización primaria (Anticipado)
1 de junio de 2019
Finalización del estudio (Anticipado)
1 de junio de 2020
Fechas de registro del estudio
Enviado por primera vez
15 de enero de 2019
Primero enviado que cumplió con los criterios de control de calidad
15 de enero de 2019
Publicado por primera vez (Actual)
17 de enero de 2019
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
18 de enero de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
17 de enero de 2019
Última verificación
1 de enero de 2019
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Carcinoma
- Neoplasias Glandulares y Epiteliales
- Enfermedades del cuello uterino
- Enfermedades uterinas
- Condiciones precancerosas
- Carcinoma in situ
- Neoplasia intraepitelial cervical
- Displasia Cervical Uterina
- Mecanismos moleculares de acción farmacológica
- Agentes antineoplásicos
- Agentes antineoplásicos inmunológicos
- Inhibidores de puntos de control inmunitarios
- Nivolumab
Otros números de identificación del estudio
- STU 032017-028
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
producto fabricado y exportado desde los EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cervix Uteri--Diseases
-
Rambam Health Care CampusTerminado
-
The University of Texas Medical Branch, GalvestonMedicem International CR s.r.o.TerminadoTrabajo de parto, inducido | Cervix Uteri-EnfermedadesEstados Unidos
-
Memorial Sloan Kettering Cancer CenterTerminadoEnfermedad trofoblástica gestacional | Cáncer uterino | Cervix Uteri NosEstados Unidos
-
Institut Mutualiste MontsourisReclutamiento
-
Fondazione Policlinico Universitario Agostino Gemelli...TerminadoAnestesia | Endometrio; Hipertrofia, Cervix | Apnea PostanestésicaItalia
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)TerminadoCáncer de cuello uterino | Cáncer renal | Cáncer uterino | HEENT Cáncer | CERVIX ÚTERI NSP | RECTOEstados Unidos
Ensayos clínicos sobre Nivolumab
-
Universitair Ziekenhuis BrusselAún no reclutando
-
Bristol-Myers SquibbReclutamientoMelanomaEspaña, Estados Unidos, Italia, Chile, Grecia, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminadoGlioblastoma recurrenteEstados Unidos
-
HUYABIO International, LLC.Bristol-Myers SquibbReclutamientoMelanoma irresecable o metastásico | Metástasis cerebral progresivaEspaña, Estados Unidos, Italia, Japón, Bélgica, Francia, Nueva Zelanda, Brasil, Corea, república de, Australia, Alemania, Singapur, Chequia, Austria, Sudáfrica, Reino Unido, Puerto Rico
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...TerminadoCáncer de cuello uterinoEstados Unidos
-
Jason J. Luke, MDArray BioPharmaActivo, no reclutandoMelanoma | Carcinoma de células renales | Tumor solido | Cáncer de pulmón de células no pequeñas | Carcinoma de células escamosas de cabeza y cuelloEstados Unidos
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActivo, no reclutandoCarcinoma avanzado de células renalesEstados Unidos
-
Bristol-Myers SquibbTerminadoCáncer de pulmónItalia, Estados Unidos, Francia, Federación Rusa, España, Argentina, Bélgica, Brasil, Canadá, Chile, Chequia, Alemania, Grecia, Hungría, México, Países Bajos, Polonia, Rumania, Suiza, Pavo, Reino Unido
-
Dan ZandbergBristol-Myers SquibbActivo, no reclutandoCarcinoma de células escamosas de cabeza y cuelloEstados Unidos
-
IRCCS San RaffaeleBristol-Myers SquibbReclutamiento